Deals
Boston Scientific to Buy Full Control of Sadra Medical
This article is for subscribers only.
Boston Scientific Corp. said it agreed to acquire closely held Sadra Medical Inc. for as much as $386 million to compete in the $2.1 billion market for transcathether heart valves that don’t require open-heart surgery.
Boston Scientific Chief Executive Ray Elliott told investors earlier today the company’s “priority growth initiatives” would include products targeting asthma, diabetes, obesity and “structural heart” therapies. Sadra’s less-invasive valve system is a structural heart therapy.